EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention

B Tchakounte Youngui, B K Tchounga, D Atwine, A Vasiliu, B Cuer, L Simo, R Okello, P Tchendjou, A Kuate Kuate, S Turyahabwe, J Cohn, S M Graham und 2 weitere

The International Journal of Tuberculosis and Lung Disease · 2025

DOI: 10.5588/ijtld.24.0311 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2025. Verfasst von B Tchakounte Youngui und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Montpellier, TransVIHMI, Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (…. Hauptthemen laut MEDLINE: Rifampin, Isoniazid, Antitubercular Agents, Tuberculosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

The WHO recommends shorter TB preventive treatment (TPT) regimens and decentralised delivery models to improve effectiveness. This study evaluated the safety of a 3-month rifampicin-isoniazid (3RH) regimen administered by community health workers (CHWs) in households in Cameroon and Uganda.





METHODS

A cluster-randomised trial was conducted among child contacts of TB patients. We compared the safety of 3RH delivered by CHWs at home (intervention) vs standard-of-care, facility-based administration of 3RH. Safety outcomes included adverse events (AEs), serious adverse events (SAEs), and adverse reactions (ARs). We described the steps from symptom identification by CHWs to classification by a clinician.





RESULTS

Of 1,316 children initiated on 3RH, AEs were reported in 8.7% (81/936) in the intervention arm versus 11.3% (43/380) in the standard-of-care arm, P = 0.15. Overall, 37 SAEs occurred in 36 children, all non-medication related. There were 16 ARs reported, occurring in 1.0% (9/936) of children in the intervention arm and 1.6% (6/380) in the standard-of-care arm, P = 0.22. During 4,608 follow-up visits, 21 children reporting AR symptoms were identified by CHWs, 16 were assessed by clinicians, and 4 ARs were confirmed.





CONCLUSIONS

The 3RH regimen was safe, including when administered by trained CHWs in community settings, supporting its use in decentralised healthcare models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinIsoniazidAntitubercular AgentsTuberculosisHumansFemaleMaleChild, PreschoolCommunity Health WorkersUgandaInfantCameroonChildFamily CharacteristicsDrug Therapy, Combination

Substanzen

RifampinIsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • University of Montpellier, TransVIHMI, Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (INSERM), Montpellier, France;, Department of Public Health Evaluation,…
  • Department of Public Health Evaluation, Research, Elizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroun.
  • Department of Clinical Research, Epicentre Research Center, Mbarara, Uganda;, Department of Clinical Research, Soar Research Foundation, Mbarara, Uganda.
  • Department of Pediatrics, Global TB Program, Baylor College of Medicine, Houston, TX, USA;, Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany;, German Center for Infection Research (DZI…
  • University of Montpellier, TransVIHMI, Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (INSERM), Montpellier, France.
  • Elizabeth Glaser Pediatric AIDS Foundation, Kampala, Uganda.

Zitieren

APA

Tchakounte Youngui, B., Tchounga, B. K., Atwine, D., Vasiliu, A., Cuer, B., Simo, L., Okello, R., Tchendjou, P., Kuate Kuate, A., Turyahabwe, S., Cohn, J., Graham, S. M., Casenghi, M., & Bonnet, M. (2025). Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.24.0311

Vancouver

Tchakounte Youngui B, Tchounga BK, Atwine D, Vasiliu A, Cuer B, Simo L, et al. Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention. The International Journal of Tuberculosis and Lung Disease. 2025. doi:10.5588/ijtld.24.0311

BibTeX
@article{TchakounteYoungui2025,
  author = {Tchakounte Youngui, B and Tchounga, B K and Atwine, D and Vasiliu, A and Cuer, B and Simo, L and Okello, R and Tchendjou, P and Kuate Kuate, A and Turyahabwe, S and Cohn, J and Graham, S M and Casenghi, M and Bonnet, M},
  title = {Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2025},
  doi = {10.5588/ijtld.24.0311}
}
Kostenlos starten →